Related Experiment Video
Updated: Aug 10, 2025
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
8.7K
Circulating DNA fragmentomics and cancer screening.
1IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, and ICM, Institut régional du Cancer de Montpellier, Montpellier 34298, France.
Cell Genomics
|February 13, 2023
Summary
Fragmentomics analyzes circulating DNA (cirDNA) size patterns to reveal nucleosome packaging. This method aids in identifying cancer origins and improving cancer screening diagnostics.
Area of Science:
- Biochemistry
- Genomics
- Oncology
Background:
- Circulating DNA (cirDNA) fragmentation patterns are influenced by chromatin organization and nucleosome packaging.
- Mononucleosomes represent the most stable cirDNA structure in circulation.
- Fragmentomics leverages these size patterns to extract biological information.
Purpose of the Study:
- To explore fragmentomics as a method for characterizing circulating DNA.
- To assess the potential of fragmentomics in determining tissue of origin and distinguishing cancer-derived cirDNA.
- To evaluate fragmentomics as a diagnostic and screening strategy for cancer.
Main Methods:
- Analysis of circulating DNA (cirDNA) size patterns (fragmentomics).
- Characterization of nucleosome positioning and occupancy.
- Application of machine learning in sophisticated fragmentomics technologies.
Main Results:
- Fragmentomics reveals information about nucleosomal DNA packing.
- Fragmentomics can determine the tissue of origin for cirDNA.
- Fragmentomics demonstrates potential in distinguishing cancer-derived cirDNA.
Conclusions:
- Fragmentomics offers a strategy for cancer characterization within individuals.
- This approach can supplement or serve as an alternative to mutation, methylation, or nucleosome positioning analyses.
- Fragmentomics holds promise for enhancing cancer diagnostics and screening.
